Update and review on the basics of pain management

Neurosciences

Volumn 16, Issue 3, 2011, Pages 203-212

  Al Sayed, Ahmed A ^a   Al Numay, Abdulaziz M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; BUPRENORPHINE; CAPSAICIN; CODEINE; DIAZEPAM; FENTANYL; HYDROMORPHONE; IBUPROFEN; INDOMETACIN; KETAMINE; LOCAL ANESTHETIC AGENT; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PENTAZOCINE; PETHIDINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUTE KIDNEY TUBULE NECROSIS; APLASTIC ANEMIA; BRONCHOSPASM; CANCER PAIN; CEREBROVASCULAR ACCIDENT; CHRONIC PAIN; CONFUSION; CONSTIPATION; DELIRIUM; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE CLASSIFICATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERANCE; DRUG USE; FIBROMYALGIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART INFARCTION; HEART RATE; HUMAN; HYPERSENSITIVITY REACTION; HYPOTHERMIA; KIDNEY PAPILLA NECROSIS; LIVER FAILURE; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MUSCLE RIGIDITY; MUSCULOSKELETAL PAIN; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; PAIN; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; RESPIRATION DEPRESSION; RESPIRATORY ACIDOSIS; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; URINE RETENTION; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; HUMANS; NEUROMUSCULAR AGENTS; PAIN;

EID: 79959364512     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Pain terms: a list with definitions and notes on usage. Recommended by IASP subcommittee on taxonomy. Pain 1979; 6: 249.
2. McCaffrey M, Ferrell BR. Nurses' knowledge of pain assessment and management: how much progress have we made? J Pain Symptom Manage 1997; 14: 175-188.
3. Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. Br J Anaesth 2008; 101: 17-24.
4. Andrew D, Greenspan JD. Mechanical and heat sensitization of cutaneous nociceptors after peripheral inflammation in the rat. J Neurophysiol 1999; 82: 2649-2656.
5. Monafo WW. Physiology of Pain. J Burn Care Rehabil 1995; 16: 345-347.
6. Turk DC, Dworkin RH. What should be the core outcomes in chronic pain clinical trials? Arthritis Res Ther 2004; 6: 151-154.
7. Salter MW. Cellular neuroplasticity mechanisms mediating pain persistence. J Orofac Pain 2004; 18: 318-324
8. Rosen SD, Camici PG. The brain-heart axis in the perception of cardiac pain: the elusive link between ischaemia and pain. Ann Med 2000; 32: 350-364.
9. Jacques A. Physiology of pain. Br J Nurs 1994; 3: 607-610. Review.
10. Burke RE. Sir Charles Sherrington's the integrative action of the nervous system: a centenary appreciation. Brain 2007; 130: 887-894.
11. Loeser JD, Treede RD. The Kyoto protocol of IASP Basic PainTerminology. Pain 2008; 137: 473-477.
12. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-1635.
13. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-251.
14. Harper AC, Harper DA, Lambert LJ, Andrews HB, Lo SK, Ross FM, et al. Symptoms of impairment, disability and handicap in low back pain: a taxonomy. Pain 1992; 50: 189-195.
15. Okifuji A. Interdisciplinary pain management with pain patients: evidence for its effectiveness. Seminars in Pain Medicine 2003; 1: 110-119.
16. Woolf CJ, Bennett GJ, Doherty M, Dubner R, Kidd B, Koltzenburg M, et al. Towards a mechanism-based classification of pain? Pain 1998; 77: 227-229.
17. Carr DB, Goudas LC. Acute pain. Lancet 1999; 353: 2051-2058. Review
18. Gunnarsdottir S, Serlin RC, Ward S. Patient-related barriers to pain management: the Icelandic Barriers Questionnaire II. J Pain Symptom Manage 2005; 29: 273-285.
19. Koyama T, McHaffie JG, Laurienti PJ, Coghill RC. The subjective experience of pain: where expectations become reality. Proc Natl Acad Sci U S A 2005; 102: 12950-12955.
20. Bertakis KD, Azari R, Callahan EJ. Patient pain in primary care: factors that influence physician diagnosis. Ann Fam Med 2004; 2: 224-230.
21. Fink R. Pain assessment: the cornerstone to optimal pain management. Proc (Bayl Univ Med Cent) 2000; 13: 236-239.
22. Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, et al. Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain 2009; 144: 35-42.
23. Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B. The Faces Pain Scale-Revised: toward acommon metric in pediatric pain measurement. Pain 2001; 93: 173-183.
24. Barkin RL, Barkin D. Pharmacologic management of acute and chronic pain: focus on drug interactions and patient-specific pharmacotherapeutic selection. South Med J 2001; 94: 756-770.
25. Hallenbeck J. Palliative care perspectives. Oxford: Oxford University Press; 2003.
26. Lockermann G. Friedrich Wilhelm Serturner, the discoverer of morphine. Journal of Chemical Education 1951; 28: 277.
27. Herman RJ, McAllister CB, Branch RA, Wilkinson GR. Effects of age on meperidine disposition. Clin Pharmacol Ther 1985; 37: 19-24.
28. Mosberg HI, Hurst R, Hruby VJ, Gee K, Yamamura HI, Galligan JJ, et al. Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. Proc Natl Acad Sci U S A 1983; 80: 5871-5874.
29. Wang RA, Randic M. Activation of mu-opioid receptor modulates GABAA receptor-mediated currents in isolated spinal dorsal horn neurons. Neurosci Lett 1994; 180: 109-113.
30. Duggan AW, North RA. Electrophysiology of opioids. Pharmacol Rev 1983; 35: 219-281.
31. Akil H, Meng F, Devine DP, Watson SJ. Molecular and Neuroanatomical Properties of the Endogenous Opioid System: Implications for Treatment of Opiate Addiction. Seminars in Neuroscience 1997; 9: 70-83.
32. Martin WR. Pharmacology of opioids. Pharmacol Rev 1983; 35: 283-323.
33. Anand KJ, Willson DF, Berger J, Harrison R, Meert KL, Zimmerman J, et al. Tolerance and withdrawal from prolonged opioid use in critically ill children. Pediatrics 2010; 125: e1208-e1225.
34. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991; 251: 85-87.
35. Bloom FE. Endogenous opioids. Histochemistry, neurophysiology, and pharmacology. Psychiatr Clin North Am 1983; 6: 365-375.
36. Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA, et al. Benzodiazepine dependence: focus onwithdrawal syndrome. Ann Pharm Fr 2009; 67: 408-413.
37. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289-295.
38. Shimomura K, Kamata O, Ueki S, Ida S, Oguri K. Analgesic effect of morphine glucuronides. Tohoku J Exp Med 1971; 105: 45-52.
39. Razaq M, Balicas M, Mankan N. Use of hydromorphone (Dilaudid) and morphine for patients with hepatic and renal impairment. Am J Ther 2007; 14: 414-416.
40. Benedetti C, Butler SH. Systemic analgesics. In: Bonica JJ, editor. The management of pain. 2nd ed. Philadelphia (PA): Lea & Febiger; 1990. p. 1640-1675.
41. Turgeon J, Gröning R, Sathyan G, Thipphawong J, Richarz U. The pharmacokinetics of a long-acting OROS hydromorphone formulation. Expert Opin Drug Deliv 2010; 7: 137-144.
42. Staahl C, Upton R, Foster DJ, Christrup LL, Kristensen K, Hansen SH, et al. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. J Clin Pharmacol 2008; 48: 619-631.
43. Rudin Ö, Lundberg JF, Hammarlund-Udenaes M, Flisberg P, Werner MU. Morphine metabolism after major liver surgery. Anesth Analg 2007; 104: 1409-1414.
44. Saari TI, Grönlund J, Hagelberg NM, Neuvonen M, Laine K, Neuvonen P, et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 2010; 66: 387-397.
45. Bodd E, Jacobsen D, Lund E, Ripel A, Morland J, Wiik-Larsen E. Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum Exp Toxicol 1990; 9: 317-321.
46. Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 1999; 90: 576-599. Review.
47. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007; 32: 562-575.
48. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002; 5: 127-138.
49. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41: 1153-1193.
50. Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology 2009; 110: 660-672.
51. Moolchan ET, Umbricht A, Epstein D. Therapeutic drug monitoring in methadone maintenance: choosing a matrix. J Addict Dis 2001; 20: 55-73.
52. Derry S, Moore RA, McQuay HJ. Single dose oral codeine, as a single agent, for acute postoperative pain in adults. Cochrane Database Syst Rev 2010 (4): CD008099.
53. Thorn CF, Klein TE, Altman RB. Codeine and morphine pathway. Pharmacogenet Genomics 2009; 19: 556-568.
54. Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer TR, Abdi S, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006; 9: 1-39. Review.
55. Armstrong SC, Wynn GH, Sandson NB. Pharmacokinetic drug interactions of synthetic opiate analgesics. Psychosomatics 2009; 50: 169-176. Review.
56. Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, et al. Buprenorphine duration of action: muopioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 2007; 61: 101-110.
57. Park I, Kim D, Song J, In C, Jeong SW, Lee S, et al. Buprederm, a new Transdermal Delivery System of Buprenorphine: Pharmacokinetic, Efficacy and Skin Irritancy Studies. Pharmaceutical Research 2008; 25: 1052-1062.
58. Buchanan WW, Kean WF. The treatment of acute rheumatism by salicin, by T.J. Maclagan--The Lancet, 1876. J Rheumatol 2002; 29: 1321-1323.
59. Sneader W. The discovery of aspirin: a reappraisal. BMJ 2000; 321: 1591-1594.
60. Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs 1996; 52 Suppl 5: 13-23.
61. Trinca F. Mechanism of Inflammation. British Medical Journal 1941; 2: 285.
62. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010; 24: 121-132.
63. Winkelmayer WC, Waikar SS, Mogun H, Solomon DH. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med 2008; 121: 1092-1098.
64. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16: 5651-5661. Review.
65. Hitomi Y, Ebisawa M, Tomikawa M, Imai T, Komata T, Hirota T, et al. Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. J Allergy Clin Immunol 2009; 124: 779-785.
66. Bagchi S. Aspirin: The Remarkable Story of a Wonder Drug. JAMA 2005; 293: 1268-1269.
67. Kapetanovic IM, Bauer KS, Tessier DM, Lindeblad MO, Zakharov AD, Lubet R, et al. Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats. Chem Biol Interact 2009; 179: 233-239.
68. Sparatore A, Perrino E, Tazzari V, Giustarini D, Rossi R, Rossoni G, et al. Pharmacological profile of a novel H2S-releasing aspirin. Free Radic Biol Med 2009; 46: 586-592.
69. Malhotra S, Shafiq N, Pandhi P. COX-2 inhibitors: a CLASS act or Just VIGORously promoted. MedGenMed 2004; 6: 6.
70. Chen LC, Ashcroft DM. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther 2006; 31: 565-576.
71. Mestre AS, Pires J, Nogueira JM, Parra JB, Carvalho AP, Ania CO. Waste-derived activated carbons for removal of ibuprofen from solution: role of surface chemistry and pore structure. Bioresour Technol 2009; 100: 1720-1726.
72. Hedner T, Everts B. The early clinical history of salicylates in rheumatology and pain. Clin Rheumatol 1998; 17: 17-25.
73. Singh N, Kumar RP, Kumar S, Sharma S, Mir R, Kaur P, et al. Simultaneous inhibition of anti-coagulation and inflammation: crystal structure of phospholipase A2 complexed with indomethacin at 1.4 A resolution reveals the presence of the new common ligand-binding site. J Mol Recognit 2009; 22: 437-445.
74. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/ paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007; 49: 670-677.
75. Bradley N. Naming of drugs. BMJ should use "paracetamol" instead of "acetaminophen" in its index. BMJ 1996; 313: 689.
76. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. Paracetamol: new vistas of an old drug. CNS Drug Rev 2006; 12: 250-275.
77. Dubach UC, Rosner B, Sturmer T. An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). N Engl J Med 1991; 324: 155-160.
78. Brodie BB, Axelrod J. The fate of acetanilide in man. J Pharmacol Exp Ther 1948; 94: 29-38.
79. Travis AS. Manufacture and Uses of the Anilines: A Vast Array of Processes and Products. KGaA, Weinheim (DE): John Wiley & Sons, Ltd; 2009.
80. Kam PCA, So A. COX-3: Uncertainties and controversies. Current Anaesthesia & Critical Care 2009; 20: 50-53.
81. Batlle-Gualda E, Roman Ivorra J, Martin-Mola E, Carbonell Abello J, Linares Ferrando LF, Tornero Molina J, et al. Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial. Osteoarthritis Cartilage 2007; 15: 900-908.
82. Jahr JS, Lee VK. Intravenous acetaminophen. Anesthesiol Clin 2010; 28: 619-645.
83. Bin Nor Aripin KN, Choonara I. The management of paracetamol poisoning. Paediatrics and Child Health 2009; 19: 492-497.
84. Scarpignato C, Hunt RH. Nonsteroidal anti-inflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010; 39: 433-464.
85. Prescott LF, Wright N. The effects of hepatic and renal damage on paracetamol metabolism and excretion following overdosage. A pharmacokinetic study. Br J Pharmacol 1973; 49: 602-613.
86. Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993; 46: 313-340. Review.
87. Nossaman VE, Ramadhyani U, Kadowitz PJ, Nossaman BD. Advances in perioperative pain management: use of medications with dual analgesic mechanisms, tramadol & tapentadol. Anesthesiol Clin 2010; 28: 647-666.
88. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 2007; 21: 499-511.
89. dos Santos TO, Estrela TG, de Azevedo VL, de Oliveira OE, Oliveira G Jr, Figueiredo Gda S. Intravenous and subcutaneous tramadol for inguinal herniorrhaphy: comparative study. Rev Bras Anestesiol 2010; 60: 522-527.
90. Garcia-Quetglas E, Azanza JR, Sadaba B, Munoz MJ, Gil I, Campanero MA. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res 2007; 55: 122-130.
91. Moore KA, Cina SJ, Jones R, Selby DM, Levine B, Smith ML. Tissue distribution of tramadol and metabolites in an overdose fatality. Am J Forensic Med Pathol 1999; 20: 98-100.
92. Livingstone KD, Lackney VK, Blauth JR, van Wijk R, Jahn MK. Genome mapping in capsicum and the evolution of genome structure in the solanaceae. Genetics 1999; 152: 1183-1202.
93. Lee Y, Howard LR, Villalon B. Flavonoids and Antioxidant Activity of Fresh Pepper (Capsicum annuum) Cultivars. J Food Sci 1995; 60: 473-476.
94. Aburjai T, Hudaib M, Tayyem R, Yousef M, Qishawi M. Ethnopharmacological survey of medicinal herbs in Jordan, the Ajloun Heights region. J Ethnopharmacol 2007; 110: 294-304.
95. Coe FG. Rama midwifery in eastern Nicaragua. J Ethnopharmacol 2008; 117: 136-157.
96. Yamamoto S, Nawata E. Use of Capsicum frutescens L. by the Indigenous Peoples of Taiwan and the Batanes Islands. Economic Botany 2009; 63: 43-59.
97. Teklehaymanot T. Ethnobotanical study of knowledge and medicinal plants use by the people in Dek Island in Ethiopia. J Ethnopharmacol 2009; 124: 69-78.
98. Jernigan KA. Barking up the same tree: a comparison of ethnomedicine and canine ethnoveterinary medicine among the Aguaruna. J Ethnobiol Ethnomed 2009; 5: 33.
99. Valadeau C, Castillo JA, Sauvain M, Lores AF, Bourdy G. The rainbow hurts my skin: medicinal concepts and plants uses among the Yanesha (Amuesha), an Amazonian Peruvian ethnic group. J Ethnopharmacol 2010; 127: 175-192.
100. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001; 24: 487-517.
101. Westaway SM. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem 2007; 50: 2589-2596.
102. Butera JA. Current and emerging targets to treat neuropathic pain. J Med Chem 2007; 50: 2543-2546.
103. Hayman M, Kam PCA. Capsaicin: A review of its pharmacology and clinical applications. Current Anaesthesia & Critical Care 2008; 19: 338-343.
104. See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician 2008; 78: 365-370.
105. Chou R, Huffman LH, American Pain Society; American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007; 147: 505-514.
106. McGeeney BE. Pharmacological management of neuropathic pain in older adults: an update on peripherally and centrally acting agents. J Pain Symptom Manage 2009; 38 (Suppl 2): S15-S27.
107. Buccafusco JJ, Terry AV Jr, Vazdarjanova A, Snutch TP, Arneric SP. Treatments for neuropathic pain differentially affect delayedmatching accuracy by macaques: effects of amitriptyline and gabapentin. Pain 2010; 148: 446-453.
108. Ripamonti C, Bandieri E. Pain therapy. Crit Rev Oncol Hematol 2009; 70: 145-159.
109. Reeve HS. Phenytoin in the treatment of trigeminal neuralgia. Lancet 1961; 277: 404.
110. Taylor CP, Vartanian MG, Andruszkiewicz R, Silverman RB. 3-alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Res 1992; 11: 103-110.
111. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009; 83: 1-43.
112. Rozen TD. Trigeminal neuralgia and glossopharyngeal neuralgia. Neurol Clin 2004; 22: 185-206.
113. Annetta MG, Iemma D, Garisto C, Tafani C, Proietti R. Ketamine: new indications for an old drug. Curr Drug Targets 2005; 6: 789-794. Review.
114. Fraceto LF, Oyama S Jr, Nakaie CR, Spisni A, de Paula E, Pertinhez TA. Interaction of local anesthetics with a peptide encompassing the IV/S4-S5 linker of the Na+ channel. Biophys Chem 2006; 123: 29-39.
115. White PF. The changing role of non-opioid analgesic techniques in the management of postoperative pain. Anesth Analg 2005; 101 (5 Suppl): S5-S22.
116. Carroll IR, Kaplan KM, Mackey SC. Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success. J Pain Symptom Manage 2008; 35: 321-326.